Tenax Therapeutics, Inc. (NASDAQ: TENX)

Tenax Therapeutics is a clinical stage pharmaceutical company focused on developing novel cardiopulmonary therapies for pulmonary hypertension and related heart failure conditions.

The company’s lead product candidate is levosimendan, which is being evaluated in the Phase 3 LEVEL trial for pulmonary hypertension resulting from heart failure with preserved ejection fraction (PH-HFpEF).

Levosimendan is an already approved drug in other indications and has been prescribed worldwide for more than twenty years, providing a well established safety profile.

A second product candidate, imatinib, is also an approved drug with a known safety profile and is being considered for future development in pulmonary arterial hypertension.

Tenax Therapeutics employs a clinician driven development approach, relying on key opinion leaders and thought leaders who are experts in pulmonary hypertension and heart failure to guide trial design and execution.

This strategy aims to reduce development risk by leveraging existing clinical data and established safety profiles while targeting specific disease pathophysiology.

Tenax Therapeutics does not currently generate revenue from product sales because its therapeutic candidates remain investigational.

The company’s reported revenue consists primarily of interest income earned on its cash and cash equivalents.

For the nine months ended September 30, 2025, interest income was $2.9 million compared with $0.9 million in the same period of the prior year.

The increase in interest income reflects higher cash balances resulting from recent financing activities and prevailing interest rates.

Any future revenue will depend on the successful development and commercialization of levosimendan or imatinib, but such revenue is not yet realized.

• no_segments_reported.

The pulmonary hypertension treatment landscape includes several approved drug classes and a number of investigational programs seeking to address unmet medical needs.

Tenax Therapeutics differentiates itself by focusing on repurposing already approved drugs rather than pursuing novel molecular entities.

This approach leverages the extensive safety and pharmacokinetic data accumulated over decades of use in other indications.

The company’s lead program targets pulmonary hypertension associated with heart failure with preserved ejection fraction, a patient subset that currently has limited therapeutic options.

By employing a clinician driven development model, Tenax Therapeutics seeks to align trial endpoints with real world clinical outcomes that matter to patients and physicians.

These factors are intended to improve the likelihood of regulatory approval and enhance the potential commercial viability of its product candidates.

The company serves patients who suffer from pulmonary hypertension and related heart failure conditions.

These patients are typically managed by cardiologists, pulmonologists, and specialized heart failure clinics.

Upon successful approval, Tenax Therapeutics anticipates that its therapies would be prescribed by treating physicians and administered in hospital and outpatient settings.

The company also engages with healthcare payers and providers to support reimbursement and access considerations.